Male patients with reduced testosterone production, such as those treated with androgen-deprivation therapy or orchiectomy, have an increased risk for osteoporosis and are likely to have been treated with bisphosphonates or a RANKL inhibitor to prevent bone loss. Here, TNFSF11 is linked to osteoporosis.